Multimodal Analgesia

Definition. Multimodal analgesia, also called balanced analgesia, is the concurrent use of several analgesic agents with different mechanisms of action, so that different points on the pain pathway are targeted at once. The aim is better pain relief with fewer side effects than any single agent gives, and in particular less opioid consumption and fewer opioid-related adverse events.

How we got here. The WHO analgesic ladder of the 1980s escalated step-wise from non-opioids to strong opioids. The 1990s brought recognition of opioid side effects and the multimodal concept; the 2000s brought ERAS (Enhanced Recovery After Surgery) protocols that built multimodal analgesia in; the opioid crisis of the 2010s drove the emphasis on opioid-sparing techniques; and the 2020s have brought standardised multimodal protocols, the expansion of regional anaesthesia and personalised pain medicine.

Why it works. Drugs acting at different sites produce an additive or synergistic effect, greater than the sum of their individual effects, and because each contributes, each can be given at a lower dose, which minimises its dose-dependent toxicity. Together they cover the nociceptive, inflammatory and neuropathic components of pain, and given preemptively they reduce the wind-up of central sensitisation.

What opioid-sparing buys. A 30-50 percent reduction in opioid consumption is achievable, and with it fall the opioid side effects: PONV (a 40 percent reduction), sedation, respiratory depression, ileus and addiction risk. Bowel function returns faster, patients mobilise earlier and hospital stay is shorter.

How it is run. Non-opioids are given scheduled, around the clock, rather than PRN, because regular dosing is more effective. Doses are weight-based and adjusted for renal and hepatic function, pain is scored frequently and the regimen adjusted, and the plan runs on past the acute phase: transition to oral agents, opioid weaning and continued physiotherapy.

The pain pathway. Pain reaches consciousness in four steps, and each step is a target:

1. Transduction (peripheral) - a noxious stimulus is converted to an electrical signal at nociceptors
2. Transmission (peripheral and spinal) - the signal is conducted along A-delta and C fibres to the dorsal horn
3. Modulation (spinal) - the signal is amplified or suppressed at dorsal horn synapses
4. Perception (supraspinal) - conscious awareness of pain in the thalamus and cortex

Peripheral targets. Transduction and transmission are where NSAIDs act, reducing prostaglandin synthesis and so nociceptor sensitisation; where local anaesthetics block sodium channels and stop the action potential propagating; where opioids reduce nociceptor excitability through peripheral mu receptors; and where corticosteroids reduce the release of inflammatory mediators.

Central targets. Modulation and perception are where paracetamol acts, through central COX inhibition and serotonergic pathways; where gabapentinoids reduce excitatory neurotransmitter release in the dorsal horn; where ketamine's NMDA antagonism prevents central sensitisation; where opioids activate spinal and supraspinal mu receptors; and where alpha-2 agonists enhance the descending inhibitory pathways.

View larger

Central sensitisation (wind-up). Repeated C-fibre stimulation progressively amplifies the responses of dorsal horn neurons: glutamate activates NMDA receptors and excitability rises. The result is hyperalgesia, increased pain to noxious stimuli, and allodynia, pain from non-noxious stimuli, and it persists beyond tissue healing, contributing to chronic pain.

Preventing it. The strategies are preemptive analgesia, meaning analgesics given before the surgical incision; NMDA antagonism with low-dose ketamine during surgery; gabapentinoids, which reduce glutamate release; and adequate regional anaesthesia, because complete afferent blockade prevents sensitisation.

Paracetamol (Acetaminophen)

Mechanism. Paracetamol inhibits COX centrally, reducing prostaglandin synthesis in the CNS, and activates serotonergic pathways that enhance descending pain inhibition. Indirect activation of CB1 receptors through the cannabinoid system, and nitric-oxide-mediated signalling, are possible further contributions.

Dosing. The adult dose is 1g PO or IV every 6 hours, to a maximum of 4g per day. In the elderly or those under 50kg it is 500-750mg every 6 hours, and in hepatic impairment the dose is reduced or the interval extended.

Evidence. A single 1g dose has an NNT of 4-5 for 50 percent pain relief, and paracetamol reduces morphine consumption by 20-30 percent. Combined with an NSAID the effect is additive and superior to either drug alone.

Contraindications and cautions. Severe hepatic impairment (Child-Pugh C) is a contraindication. In chronic alcohol use the maximum daily dose falls to 2-3g, and glutathione depletion states, such as malnutrition, HIV and chronic illness, are the other cautions.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Mechanism. NSAIDs inhibit the COX enzymes and so prostaglandin synthesis. COX-1 is constitutive and serves gastric protection, platelet function and renal blood flow; COX-2 is inducible and drives inflammation, pain and fever. The effect is both peripheral and central, reducing inflammatory sensitisation.

Evidence. NSAIDs reduce morphine consumption by 30-40 percent, and the combination with paracetamol is synergistic. COX-2 selective and non-selective agents give similar analgesia; the selective agents cause less GI bleeding but carry increased cardiovascular risk at high doses.

Contraindications. The list mixes absolute and relative:

• Active peptic ulcer disease - absolute contraindication for non-selective NSAIDs
• Severe renal impairment (eGFR less than 30 mL/min) - avoid or use cautiously
• History of GI bleeding - use a COX-2 selective agent with a PPI
• Cardiovascular disease - avoid high-dose COX-2 inhibitors
• Bleeding risk - non-selective NSAIDs impair platelet function; avoid perioperatively if this is a concern
• Third trimester pregnancy - risk of premature closure of the ductus arteriosus
• Aspirin-sensitive asthma - cross-reactivity possible

Gabapentinoids

The drugs. Gabapentin requires dose escalation and three-times-daily dosing. Pregabalin has higher bioavailability, twice-daily dosing and a faster onset.

Mechanism. Both bind the alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn, reducing calcium influx into presynaptic terminals and so the release of excitatory neurotransmitters, glutamate and substance P, which prevents central sensitisation.

Dosing. Gabapentin is given as a single 600-1200mg dose 1-2 hours before surgery, then 300mg three times daily postoperatively, titrated to 300-600mg three times daily. Pregabalin is 150-300mg 1-2 hours before surgery, then 75mg twice daily, titrated to 150mg twice daily. Both are renally cleared, and the dose is reduced if CrCl is less than 60 mL/min.

Evidence, and the retreat from routine use. A meta-analysis of 281 RCTs and 24,682 patients found the reduction in pain intensity below the minimally important difference at every timepoint, no effect on chronic postsurgical pain, and more dizziness and visual disturbance. Routine perioperative use is therefore no longer supported by high-quality evidence, and the historical "25-30 percent opioid-sparing" claim has not held up in pooled data. Reserve gabapentinoids for a genuine neuropathic component (nerve injury, amputation, some spine surgery), decided case by case.

Side effects. Sedation is the dose-limiting one:

• Sedation (20-30 percent) - dose-limiting, avoid in the elderly
• Dizziness (15-20 percent)
• Visual disturbances (blurred vision)
• Peripheral oedema
• Cognitive impairment (especially the elderly or cognitively impaired)

Cautions. Combined with opioids, gabapentinoids cause synergistic respiratory depression, the key safety signal, especially in the elderly or those with sleep-disordered breathing. They may worsen the muscle weakness of myasthenia gravis.

Ketamine

Mechanism. Ketamine is an NMDA receptor antagonist: it prevents glutamate-mediated excitation and so central sensitisation and wind-up. It also interacts with opioid receptors, which may reverse opioid-induced hyperalgesia, and it modulates cytokine release, an anti-inflammatory effect.

Low-dose (sub-anaesthetic) dosing. The protocols are:

• Intraoperative infusion: 0.1-0.5 mg/kg/hr (typically 0.2 mg/kg/hr)
• Bolus: 0.1-0.25 mg/kg IV at induction
• Postoperative infusion: 0.05-0.2 mg/kg/hr for 24-48 hours

Evidence. Ketamine reduces morphine consumption by 15-30 percent, and is most effective in opioid-tolerant patients and in procedures with high pain intensity. There is a possible benefit in preventing chronic postsurgical pain.

Side effects. The psychomimetic effects, dysphoria, hallucinations and nightmares, are dose-dependent. Nausea is less common than with opioids; hypertension and tachycardia reflect its sympathomimetic action; and respiratory depression is minimal at low doses.

Contraindications. Ketamine is avoided in:

• Psychotic disorders - may precipitate psychosis
• Uncontrolled hypertension - sympathomimetic effects
• Raised intracranial pressure - increases cerebral blood flow and ICP
• Ischaemic heart disease - caution, because myocardial oxygen demand rises

Local Anaesthetics

Mechanism. Local anaesthetics block sodium channels, preventing the generation and propagation of action potentials, a reversible block of nerve conduction. The blockade is differential: smaller fibres, carrying pain and autonomic traffic, are blocked before motor fibres.

Applications. Local anaesthetics reach the multimodal regimen as peripheral nerve blocks (femoral, sciatic, interscalene, adductor canal, TAP block), neuraxial techniques (spinal and epidural analgesia), local infiltration (wound infiltration, intra-articular injection) and continuous catheters (peripheral nerve catheters, wound catheters). Allergy and local infection at the injection site are the contraindications.

Toxicity. CNS toxicity presents as tinnitus, a metallic taste, perioral numbness and seizures; cardiovascular toxicity as arrhythmias and cardiac arrest, and bupivacaine is the most cardiotoxic of the agents.

Why regional. Regional anaesthesia is the gold standard for major procedures: peripheral nerve blocks (femoral, sciatic, interscalene) or neuraxial techniques (epidural, spinal) provide superior analgesia to systemic opioids. Whether a single shot or a continuous catheter is used depends on the surgery and the expected duration of pain.

Peripheral Nerve Blocks

Femoral block. Indicated for TKA, femoral shaft fracture and anterior thigh procedures, it gives excellent quadriceps analgesia at the price of quadriceps weakness and fall risk. The motor-sparing alternative is the adductor canal block.

Adductor canal block. Indicated for TKA and ACL reconstruction, it preserves quadriceps strength, so fall risk is lower, and covers the medial knee and distal femur. Its analgesia is non-inferior to the femoral block for TKA, and it is now the preferred block for total knee arthroplasty.

Sciatic block. Indicated for ankle and foot surgery, the posterior pain of TKA and below-knee amputation, by the popliteal (distal), subgluteal or anterior approach. It covers the posterior knee and the entire lower leg and foot, lasts 12-24 hours as a single shot and 48-72 hours with a catheter, and is essential for complete analgesia in lower limb procedures.

Interscalene block. The block for shoulder surgery, arthroplasty and rotator cuff repair, covering the shoulder and proximal humerus. Its complications are phrenic nerve palsy, which occurs in 100 percent, and Horner syndrome.

Supraclavicular block. The block for elbow, forearm and hand surgery, where the brachial plexus anatomy is compact. The risk is pneumothorax, less than 1 percent with ultrasound.

Neuraxial Analgesia

Epidural indications. Epidural analgesia is indicated for:

• Major spine surgery (multi-level fusion)
• Lower limb surgery with expected severe pain (revision arthroplasty)
• Bilateral lower limb procedures

Technique. The catheter is placed thoracic (T8-L1) or lumbar (L2-L4) depending on the surgical level, and runs bupivacaine 0.125-0.25 percent plus fentanyl 2-4 mcg/mL at 4-10 mL/hr for 48-72 hours postoperatively.

The trade. In its favour: analgesia superior to systemic opioids, bilateral coverage, a 60-80 percent reduction in opioid use, and easier mobilisation and physiotherapy. Against it: hypotension from sympathetic blockade, managed with fluids and vasopressors; motor blockade that delays mobilisation if the concentration is too high; urinary retention, so a catheter is required; and the rare complications of epidural haematoma (1 in 10,000), abscess and permanent neurological injury.

The arthroplasty protocols. Both share one skeleton: oral non-opioids before surgery, a spinal or a peripheral block plus local infiltration and IV dexamethasone during it, then scheduled non-opioids with PRN oxycodone afterwards. They differ in intensity, because THA is generally less painful than TKA.

A note on the gabapentin. It appears in both protocols as the historical preemptive agent. On the pooled evidence set out under Gabapentinoids, routine use is no longer supported, so it is reserved for a genuine neuropathic component rather than given to every arthroplasty patient.

Differential of the Patient With Uncontrolled Postoperative Pain

Severe pain despite a multimodal regimen is itself a clinical problem with a differential. Do not simply escalate opioids: work through the causes, because several require a specific intervention rather than more analgesia.

Global Burden and Why It Matters

Inadequately controlled acute postoperative pain remains common worldwide and is consistently associated with delayed mobilisation, higher complication rates, prolonged stay and an increased risk of persistent postsurgical pain. Major joint arthroplasty volumes are rising globally with ageing populations, so the perioperative analgesic strategy is a high-frequency, high-impact clinical decision in every health system. The shared global driver of the last decade has been opioid stewardship: reducing both inpatient and post-discharge opioid exposure while maintaining function-enabling analgesia. Multimodal, opioid-sparing analgesia embedded within enhanced-recovery pathways is the converged international answer.

Major Guidance, Side by Side

Recommendations from the leading bodies are broadly concordant - paracetamol plus an NSAID/COX-2 backbone, regional or local-infiltration techniques, and opioids reserved as rescue. The main areas of genuine divergence are the role of gabapentinoids and the choice between intrathecal morphine and peripheral techniques.

Convergent Points of International Consensus

• Paracetamol + NSAID/COX-2 is the non-opioid backbone - scheduled, not PRN, unless contraindicated (Ong meta-analysis supports the combination).
• Regional and local-infiltration techniques are central for major joint and limb surgery (adductor canal block + LIA for TKA per PROSPECT).
• Opioids are rescue analgesics, with deliberate limits on post-discharge quantity to reduce persistent use.
• A single intra-operative dose of dexamethasone improves analgesia and reduces PONV and is now widely recommended for arthroplasty.

Genuine Areas of Practice Variation

• Gabapentinoids: historically routine, now discouraged for unselected patients after large meta-analytic data (Verret) showed sub-threshold benefit and real harms; several systems have reclassified them as controlled drugs. Reserve for a clear neuropathic component.
• Intrathecal morphine vs peripheral block/LIA: some centres still use low-dose intrathecal morphine for arthroplasty; PROSPECT positions it as a fall-back when block and LIA are not feasible, partly because of pruritus, urinary retention and delayed respiratory depression.
• Resource setting: in limited-resource environments where ultrasound and catheter services are scarce, reliance shifts toward scheduled oral non-opioids, surgeon-delivered LIA and judicious opioids; ultrasound-guided regional services and acute pain teams are concentrated in higher-resource centres.

Registry and System-Level Evidence

Although multimodal analgesia is not itself tracked by joint registries, the major arthroplasty registries (NJR for England and Wales, AJRR in the USA, AOANJRR in Australia, the Swedish and Norwegian registries, and the New Zealand Joint Registry) document the rise of same-day and short-stay arthroplasty that opioid-sparing multimodal pathways have enabled. Real-time prescription-monitoring systems in several jurisdictions now track perioperative and post-discharge opioid prescribing, reflecting the global shift toward measurable opioid stewardship.

Relevance Across Examinations

Multimodal analgesia is high-yield for every major orthopaedic board. Examiners reliably probe: the rationale for opioid-sparing, the non-opioid backbone, procedure-specific regional choices (adductor canal block vs femoral block, interscalene for shoulder), the NSAID-and-bone-healing controversy, the modern retreat from routine gabapentinoids, and recognition of the patient whose pain signals a complication rather than under-dosing.